Ticagrelor not better than aspirin in lowering graft failure post CABG: TiCAB study

TCTMD Nov 29, 2018

Results from the TiCAB study have shown that Ticagrelor monotherapy is no better than aspirin in reducing the chances of graft failure in the first year following a coronary artery bypass grafting (CABG).

The drug, a P2Y12 inhibitor was thought to be more effective than aspirin at lowering platelet aggregation, believed to be a key mediator in graft failure. The TiCAB results showed that of 1900 patients involved, there wasn't any significant difference in the rate of CV death, MI, stroke, or repeat revascularisation between the two groups- one on aspirin and the other on ticagrelor. 

Another issue that the researchers pointed out was the use of aspiring and ticagrelor with opiates such as fentanyl after surgery. While aspirin is absorbed through the stomach and show a rapid onset of action even in patients on fentanyl, ticagrelor is absorbed through the intestines and its absorption is also delayed by opiates such as fentanyl. This could have been one important aspect that could have been disadvantageous for ticagrelor in the study. 


Information for the article was sourced from TCTMD. Read the original here.

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen